S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma

Clinical Biochemistry

Volumn 37, Issue 7, 2004, Pages 512-518

  Harpio, Riikka ^a   Einarsson, Roland ^a  

^a Diasorin SpA   (Italy)

Author keywords

Malignant melanoma; S100 proteins; S100B; Tumor marker

Indexed keywords

BIOLOGICAL MARKER; CALCYCLIN; PROTEIN S 100; PROTEIN S100B;

CANCER DIAGNOSIS; CANCER STAGING; CONCENTRATION (PARAMETERS); DECISION MAKING; EVALUATION; FOLLOW UP; HUMAN; IMMUNOASSAY; LABORATORY TEST; LYMPH NODE; MASS; MELANOMA; METASTASIS; MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FAMILY; PROTEIN FUNCTION; RELAPSE; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR GROWTH;

FOLLOW-UP STUDIES; HUMANS; IMMUNOASSAY; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; RECURRENCE; S100 PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 3042685214     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2004.05.012     Document Type: Review

References (74)

1. Gaynor R., Irie R., Morton D. Herschman HR, S 100 protein is present in cultured human malignant melanomas. Nature. 286:1980;400-401
2. Donato R. Perspectives in S-100 protein biology, Review article. Cell Calcium. 12:1991;713-726
3. Gaynor R., Herschman H.R., Irie R., Jones P., Morton D., Cochran A. S 100 protein: a marker for human malignant melanomas? Lancet. 1:1981;869-871
4. Donato R. S-100 proteins. Cell Calcium. 7:1986;123-145
5. Donato R. S 100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 33:2001;637-668
6. Kawasaki H., Nakayama S., Kretsinger R.H. Classification and evolution of EF-hand proteins. Biometals. 11:1998;277-295
7. Zimmer D.B. Examination of the calcium-modulated protein S 100 alpha and its target proteins in adult and developing skeletal muscle. Cell Motil. Cytoskeleton. 20:1991;325-337
8. Heizmann C.W., Cox J.A. New perspectives on S 100 proteins: a multi-functional Ca(2+)-Zn(2+)- and Cu(2+)-binding protein family. Biometals. 11:1998;383-397
9. Schäfer B.W., Fritschy J.M., Murmann P., et al. Brain S 100A5 is a novel calcium-, zinc-, and copper ion-binding protein of the EF-hand superfamily. J. Biol. Chem. 275:2000;30623-30630
10. Moore B.W. A soluble protein characteristic of the nervous system. Biochem Biophys. Res. Commun. 19:1965;739-744
11. Haglid K., Carlsson C.A., Stavrou D. An immunological study of human brain tumors concerning the brain specific protein S-100 and 14.3.2. Acta Neuropathol. (Berl.). 24:1973;187-196
12. Isobe T., Okuyama T. The amino-acid sequence of the alpha subunit in bovine brain S-100a protein. Eur. J. Biochem. 116:1981;79-86
13. Schäfer B.W., Wicki R., Engelkamp D., Mattei M.G., Heizmann C.W. Isolation of a YAC clone covering a cluster of nine S 100 genes on human chromosome 1q21: rationale for a new nomenclature of the S 100 calcium-binding protein family. Genomics. 25:1995;638-643
14. Heizmann C.W., Fritz G., Schafer B.W. S 100 proteins: structure, functions and pathology. Front Biosci. 7:2002;1356-1368
15. Fano G., Biocca S., Fulle S., Mariggio M.A., Belia S., Calissano P. The S-100: a protein family in search of a function. Prog. NeuroBiol. 46:1995;71-82
16. Donato R. Functional roles of S 100 proteins, calcium-binding proteins of the EF-hand type. Biochim. Biophys. Acta. 1450:1999;191-231
17. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta. 1498:2000;99-111
18. Zimmer D.B., Cornwall E.H., Landar A., Song W. The S 100 protein family: history, function, and expression. Brain Res. Bull. 37:1995;417-429
19. Kligman D., Hilt D.C. The S 100 protein family. Trends Biochem. Sci. 13:1988;437-443
20. Ueda S., Kokotos Leonardi E.T., Bell J. III, Azmitia E.C. Serotonergic sprouting into transplanted C-6 gliomas is blocked by S-100 beta antisense gene. Brain Res. Mol. Brain Res. 29:1995;365-368
21. Hu J., Ferreira A., Van Eldik L.J. S 100beta induces neuronal cell death through nitric oxide release from astrocytes. J. Neurochem. 69:1997;2294-2301
22. Ghanem G., Loir B., Morandini R., et al. On the release and half-life of S 100B protein in the peripheral blood of melanoma patients. Int. J. Cancer. 94:2001;586-590
23. Molina R., Navarro J., Filella X., Castel T., Ballesta A.M. S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol. 23:2002;39-44
24. 2+-dependent manner. Protein Sci. 7:1998;794-798
25. Ilg E.C., Schafer B.W., Heizmann C.W. Expression pattern of S 100 calcium-binding proteins in human tumors. Int. J. Cancer. 68:1996;325-332
26. Yonemura Y., Endou Y., Kimura K., et al. Inverse expression of S 100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin. Cancer Res. 6:2000;4234-4242
27. Guo X.J., Chambers A.F., Parfett C.L., et al. Identification of a serum-inducible messenger RNA (5B10) as the mouse homologue of calcyclin: tissue distribution and expression in metastatic, ras-transformed NIH 3T3 cells. Cell Growth Differ. 1:1990;333-338
28. Trocha S., Gupta R.K., Morton D.L. Tumour markers in melanoma. Diamandis E.P., Fritsche H.A., Lilja H., Chan D.W., Schwartz M.K. Tumor markers. Physiology, pathobiology, technology and clinical applications. 2002;361-374 AACC Press, Washington, DC
29. Misotten G.S., Tang N.E., Korse C.M., Hurks H.M., de Wolff-Rouendaal D., Keunen J.E., et al. Prognostic value of S-100beta serum concentration in patients with uveal melanoma. Arch. Ophthalmol. 121:2003;1117-1119
30. Wicki R., Franz C., Scholl F.A., Heizmann C.W., Schafer B.W. Repression of the candidate tumor suppressor gene S 100A2 in breast cancer is mediated by site-specific hypermethylation. Cell Calcium. 22:1997;243-254
31. Kyriazanos I.D., Tachibana M., Dhar D.K., et al. Expression and prognostic significance of S 100A2 protein in squamous cell carcinoma of the esophagus. Oncol. Rep. 9:2002;503-510
32. Rosty C., Ueki T., Argani P., et al. Overexpression of S 100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am. J. Pathol. 160:2002;45-50
33. Taylor S., Herrington S., Prime W., Rudland P.S., Barraclough R. S 100A4 (p9Ka) protein in colon carcinoma and liver metastases: association with carcinoma cells and T-lymphocytes. Br. J. Cancer. 86:2002;409-416
34. Nakamura T., Ajiki T., Murao S., et al. Prognostic significance of S 100A4 expression in gallbladder cancer. Int. J. Oncol. 20:2002;937-941
35. Bjornland K., Bratland A., Rugnes E., Pettersen S., Johansen H.A.T., Aase A.O., et al. Expression of matrix metalloproteinases and the metastasis-associated gene S 100A4 in human neuroblastoma and primitive neuroectodermal tumor cells. J. Pedriatr. Surg. 36:2001;1040-1044
36. Gongoll S., Peters G., Mengel M., et al. Prognostic significance of calcium-binding protein S 100A4 in colorectal cancer. Gastroenterology. 123:2002;1478-1484
37. Gupta S., Hussain T., MacLennan G.T., Fu P., Patel J., Mukhtar H. Differential expression of S 100A2 and S 100A4 during progression of human prostate adenocarcinoma. J. Clin. Oncol. 21:2003;106-112
38. Maelandsmo G.M., Florenes V.A., Mellingsaeter T., Hovig E., Kerbel R.S., Fodstad O. Differential expression patterns of S 100A2, S 100A4 and S 100A6 during progression in human malignant melanoma. Int. J. Cancer. 74:1997;464-469
39. El Rifai W., Moskaluk C.A., Abdrabbo M.K., et al. Gastric cancers overexpress S 100A calcium-binding proteins. Cancer Res. 62:2002;6823-6826
40. Ribe A., McNutt N.S. S 100A Protein expression in the distinction between lentigo maligna and pigmented actinic keratosis. Am. J. Dermatopathol. 25:2003;93-99
41. van Eldik L.J., Jensen R.A., Ehrenfried B.A., Whetsell W.O. Jr. Immunohistochemical localization of S 100 beta in human nervous system tumors by using monoclonal antibodies with specificity for the S 100 beta polypeptide. J. Histochem. Cytochem. 34:1986;977-982
42. Stefansson K., Wollmann R.L., Moore B.W., Arnason B.G. S-100 protein in human chondrocytes. Nature. 295:1982;63-64
43. Cocchia D., Michetti F., Donato R. Immunochemical and immuno-cytochemical localization of S-100 antigen in normal human skin. Nature. 294:1981;85-87
44. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann. Surg. 172:1970;902-908
45. Cochran A.J., Wen D.R., Herschman H.R., Gaynor R.B. Detection of S-100 protein as an aid to the identification of melanocytic tumors. Int. J. Cancer. 30:1982;295-297
46. von Schoultz E., Hansson L.O., Djureen E., et al. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res. 6:1996;133-137
47. Guo H.B., Stoffel-Wagner B., Bierwirth T., Mezger J., Klingmuller D. Clinical significance of serum S 100 in metastatic malignant melanoma. Eur. J. Cancer. 31A:1995;1898-1902
48. Nakajima T., Watanabe S., Sato Y., Kameya T., Shimosato Y., Ishihara K. Immunohistochemical demonstration of S 100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer. 50:1982;912-918
49. Joseph E. Tumor markers in malignant melanoma: a review. Tumor Marker Update. 9:1997;157-163
50. Heizmann C.W. S 100B protein in clinical diagnostics, assay specificity. Clin. Chem. 50:2004;249-251
51. Marks A., Petsche D., O'Hanlon D., et al. S 100 protein expression in human melanoma cells, comparison of levels of expression among different cell lines and individual cells in different phases of the cell cycle. Exp. Cell Res. 187:1990;59-64
52. Brochez L., Naeyaert J.-M. Serological markers for melanoma. Br. J. Dermatol. 143:2000;256-268
53. Berking C., Schlupen E.M., Schrader A., Atzpodien J., Volkenandt M. Tumor markers in peripheral blood of patients with malignant melanoma, multimarker RT-PCR versus a luminoimmunometric assay for S-100. Arch. Dermatol. Res. 291:1999;479-484
54. Hansson L.O., von Schoultz E., Djureen E., Hansson J., Nilsson B., Ringborg U. Prognostic value of serum analyses of S-100 protein beta in malignant melanoma. Anticancer Res. 17:1997;3071-3073
55. Djureen-Mårtensson E., Hansson L.O., Nilsson B., et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J. Clin. Oncol. 19:2001;824-831
56. Hauschild A., Engel G., Brenner W., et al. S 100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology. 56:1999;338-344
57. Krähn G., Kaskel P., Sander S., et al. S 100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 21:2001;1311-1316
58. Schmitz C., Brenner W., Henze E., Christophers E., Hauschild A. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res. 20:2000;5059-5063
59. Schultz E.S., Diepgen T.L., Von Den D.P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br. J. Dermatol. 138:1998;426-430
60. Bonfrer J.M., Korse C.M., Israels S.P. Serum S-100 has prognostic significance in malignant melanoma. Anticancer Res. 17:1997;2975-2977
61. Kärnell R., von Schoultz E., Hansson L.O., Nilsson B., Arstrand K., Kagedal B. S 100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2- carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res. 7:1997;393-399
62. Henze G., Dummer R., Joller-Jemelka H.I., Boni R., Burg G. Serum S 100-a marker for disease monitoring in metastatic melanoma. Dermatology. 194:1997;208-212
63. Bonfrer J.M., Korse C.M., Nieweg O.E., Rankin E.M. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br. J. Cancer. 77:1998;2210-2214
64. Abraha H.D., Fuller L.C., Du Vivier A.W., Higgins E.M., Sherwood R.A. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br. J. Dermatol. 137:1997;381-385
65. Hauschild A., Michaelsen J., Brenner W., et al. Prognostic significance of serum S 100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res. 9:1999;155-161
66. Jury C.S., McAllister E.J., MacKie R.M. Rising levels of serum S 100 protein precede other evidence of disease progression in patients with malignant melanoma. Br. J. Dermatol. 143:2000;269-274
67. Hauschild A., Engel G., Brenner W., et al. Predictive value of serum S 100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br. J. Dermatol. 140:1999;1065-1071
68. Kaskel P., Berking C., Sander S., Volkenandt M., Peter R.U., Krähn G. S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma. J. Am. Acad. Dermatol. 41:1999;962-969
69. Hamberg A.P., Korse C.M., Bonfrer J.M.G., de Gast G.C. Serum S 100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 13:2003;45-49
70. Hauschild A. The use of serological tumor markers for malignant melanoma. Onkologie. 20:1997;462-465
71. Huang C.L., Provost N., Marghoob A.A., Kopf A.W., Levin L., Bart R.S. Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J. Am. Acad. Dermatol. 39:1998;451-463
72. Miliotes G., Lyman G.H., Cruse C.W., et al. Evaluation of new putative tumor markers for melanoma. Ann. Surg. Oncol. 1996;558-563
73. Buer J., Probst M., Franzke A., et al. Elevated serum levels of S 100 and survival in metastatic malignant melanoma. Br. J. Cancer. 75:1997;1373-1376
74. Banfalvi T., Udvarhelyi N., Orosz Z., Gergye M., Gilde K., Timar J. Heterogeneous S-100B protein expression patterns in malignant melanoma and association with serum protein levels. Oncology. 64:2003;374-379